TECH - Bio-Techne Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
179.98
-0.16 (-0.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close180.14
Open179.69
Bid0.00 x 800
Ask0.00 x 800
Day's Range177.58 - 180.25
52 Week Range117.42 - 183.90
Volume140,200
Avg. Volume195,935
Market Cap6.763B
Beta0.83
PE Ratio (TTM)54.71
EPS (TTM)3.29
Earnings DateOct 29, 2018 - Nov 2, 2018
Forward Dividend & Yield1.28 (0.72%)
Ex-Dividend Date2018-08-16
1y Target Est190.86
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Bio-Techne Corp.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Bio-Techne Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • PR Newswire8 days ago

    Bio-Techne Introduces GMP Small Molecules for Stem Cell Therapy Development

    MINNEAPOLIS, Aug. 8, 2018 /PRNewswire/ -- Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies. Bio-Techne has a highly-qualified team who have full control over the cGMP process, meaning we can ensure: a quality assured manufacturing system, guaranteed batch-to-batch consistency, traceability from starting material to final product, and consistency of supply. GMP compounds are synthesized in accordance with relevant sections of ICH Q7 guidelines, and are classified as tier 2 risk in the USP guidelines.

  • PR Newswire9 days ago

    Bio-Techne Declares Dividend

    MINNEAPOLIS , Aug. 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2018 ...

  • ACCESSWIRE9 days ago

    Bio-Techne Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Bio-Techne Corporation (NASDAQ: TECH ) will be discussing their earnings results in their Q4 Earnings Call to be held on August 7, 2018 at 9:00:00 AM Eastern ...

  • PR Newswire9 days ago

    Bio-Techne Releases Fourth Quarter Fiscal 2018 Results

    MINNEAPOLIS , Aug. 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2018 . Fourth Quarter and Full Year FY2018 Snapshot ...

  • PR Newswire14 days ago

    Bio-Techne Announces 2018 Investor Day And Webcast

    MINNEAPOLIS , Aug. 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host its 2018 Investor Day on Friday, September 7, 2018 , starting at 9:00 a.m. EDT ...

  • PR Newswire15 days ago

    Bio-Techne Corporation Completed Its Acquisition of Exosome Diagnostics, Inc.

    MINNEAPOLIS, Aug.1, 2018 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc. The transaction consideration includes an upfront payment of $250 million plus an additional $325 million that can be maximally earned through calendar year 2022 upon reaching certain performance milestones. With this acquisition, Minneapolis-based Bio-Techne now has a world-wide workforce in excess of 2,100 and has expanded its global reach with subsidiaries in every major geographic market. This acquisition continues to build on Bio-Techne's strategy to expand its market reach beyond its legacy research market into the liquid biopsy diagnostic arena with the introduction of Exosome Diagnostics' non-invasive prostate molecular test (EPI) to help physicians better serve their patients when considering the need for a prostate biopsy.

  • GlobeNewswire15 days ago

    Market Trends Toward New Normal in Horizon Global, Bio-Techne, Adamis Pharmaceuticals, Kadant, Semgroup, and Provident Financial Services — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Horizon ...

  • PR Newswire23 days ago

    Bio-Techne Introduces New Member of the Simple Western™ Family, with IR/NIR Detection Capabilities

    MINNEAPOLIS , July 24, 2018 /PRNewswire/ -- Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess. ...

  • InvestorPlacelast month

    5 Tips for Making Money in Penny Stocks

    The definition of penny stocks is entirely subjective. What I think constitutes a risky penny stock, you might feel is a robust, thriving enterprise. From there, I’ll tackle the five rules investors should follow to be successful in trading penny stocks.

  • PR Newswirelast month

    Bio-Techne To Host Conference Call On August 7, 2018 To Announce Fourth Quarter 2018 Financial Results

    MINNEAPOLIS , July 12, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. CDT to review fourth ...

  • Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets
    PR Newswirelast month

    Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets

    Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results MINNEAPOLIS , July 10, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique ...

  • See what the IHS Markit Score report has to say about Bio-Techne Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Bio-Techne Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Bio-Techne Expands RNAscope® Assay Services Portfolio to Shorten Development Times and Save Costs
    PR Newswire2 months ago

    Bio-Techne Expands RNAscope® Assay Services Portfolio to Shorten Development Times and Save Costs

    MINNEAPOLIS, June 26, 2018 /PRNewswire/ -- Bio-Techne has added new capabilities and options to its Advanced Cell Diagnostics (ACD)-branded RNAscope® and BaseScope™ in situ hybridization (ISH) Assay Services Portfolio to improve biotech and pharma discovery timelines and costs. Responding to customer needs, the company has expanded its pre-validated tissue bank with new tissues and disease types and created pre-collected immuno-oncology datasets, profiling key targets and immune checkpoint markers.

  • PR Newswire2 months ago

    Bio-Techne To Acquire Exosome Diagnostics, Inc.

    MINNEAPOLIS and WALTHAM, Mass., June 25, 2018 /PRNewswire/ -- Bio-Techne Corporation (TECH) announced today that it has reached agreement to acquire Exosome Diagnostics, Inc. for $250 million in cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones. The transaction is expected to close in July or early August 2018. The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.

  • Is Bio-Techne Corporation (NASDAQ:TECH) A Financially Strong Company?
    Simply Wall St.2 months ago

    Is Bio-Techne Corporation (NASDAQ:TECH) A Financially Strong Company?

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Bio-Techne Corporation (NASDAQ:TECH) with a market-capitalization of US$6.15b, rarely draw their attention. Despite this, commonly overlooked mid-capsRead More...

  • PR Newswire2 months ago

    Bio-Techne To Acquire Quad Technologies

    MINNEAPOLIS, June 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (TECH) announced today it has reached agreement to acquire all of the stock of QT Holdings Corporation d/b/a Quad Technologies. "We are extremely excited to welcome Quad Technologies and its line of advanced reagents to Bio-Techne," commented Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne.  "We are confident that the novel, releasable, customizable, non-magnetic, Quickgel™ technologies, offered by Quad Technologies for cell separation and activation, represent a breakthrough in process improvements for clinical grade cell and gene therapy applications as well as for research use."  Quad Technologies has developed QuickGel™ microparticles that are easily modifiable with antibodies and can serve as the substrate for traditional "bead-based" separation and cell activation with the added benefit of being able to quickly dissolve them after use.

  • Bio-Techne To Present At The William Blair 38th Annual Growth Stock Conference
    PR Newswire2 months ago

    Bio-Techne To Present At The William Blair 38th Annual Growth Stock Conference

    MINNEAPOLIS , June 4, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the William Blair 38 th Annual ...

  • Bio-Techne To Present At The Jefferies 2018 Healthcare Conference
    PR Newswire3 months ago

    Bio-Techne To Present At The Jefferies 2018 Healthcare Conference

    MINNEAPOLIS , May 24, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies 2018 Healthcare ...

  • Better Know Biotech: 2 Stocks You Ought to Know About
    Motley Fool3 months ago

    Better Know Biotech: 2 Stocks You Ought to Know About

    These two under-followed biotech stocks could be worth owning in your portfolio.

  • Bio-Techne To Present At The UBS Global Healthcare Conference
    PR Newswire3 months ago

    Bio-Techne To Present At The UBS Global Healthcare Conference

    MINNEAPOLIS , May 10, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the UBS Global Healthcare Conference ...

  • When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
    Simply Wall St.3 months ago

    When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

    Bio-Techne Corporation (NASDAQ:TECH), a life sciences company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGS. WithRead More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of TECH earnings conference call or presentation 2-May-18 1:00pm GMT

    Q3 2018 Bio-Techne Corp Earnings Call

  • Does Bio-Techne Corporation’s (NASDAQ:TECH) PE Ratio Warrant A Sell?
    Simply Wall St.3 months ago

    Does Bio-Techne Corporation’s (NASDAQ:TECH) PE Ratio Warrant A Sell?

    Bio-Techne Corporation (NASDAQ:TECH) is currently trading at a trailing P/E of 49.2x, which is higher than the industry average of 39x. While this makes TECH appear like a stock toRead More...

  • PR Newswire3 months ago

    Bio-Techne Releases Third Quarter Fiscal 2018 Results

    MINNEAPOLIS , May 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2018 . Third Quarter FY2018 Snapshot Third quarter ...